Theravance Biopharma - TBPH Stock Forecast, Price & News

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Analyst Ratings Changes

A number of brokerages have issued reports on TBPH. HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Theravance Biopharma in a research report on Thursday, July 14th. SVB Leerink started coverage on Theravance Biopharma in a research report on Monday, May 23rd. They set an "outperform" rating and a $12.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $11.75.

Theravance Biopharma Trading Up 1.3 %

Shares of TBPH Stock opened at $9.83 on Wednesday. The firm has a fifty day moving average price of $9.04 and a 200 day moving average price of $9.34. The company has a market cap of $751.28 million, a P/E ratio of -7.23 and a beta of 0.69. Theravance Biopharma has a 12 month low of $6.10 and a 12 month high of $14.28.

Theravance Biopharma (NASDAQ:TBPH - Get Rating) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.06). During the same period in the previous year, the business posted ($0.80) EPS. On average, equities analysts forecast that Theravance Biopharma will post -0.75 EPS for the current year.

Insider Buying and Selling

In related news, SVP Richard A. Graham sold 15,086 shares of the business's stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $8.79, for a total transaction of $132,605.94. Following the completion of the transaction, the senior vice president now owns 369,651 shares in the company, valued at $3,249,232.29. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 4.80% of the company's stock.